Gene therapy for prostate cancer

Hematology/Oncology Clinics of North America

Volumn 12, Issue 3, 1998, Pages 649-664

  Malkowicz, S B ^a   Johnson, J O ^a  

^a HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

VIRUS VECTOR;

ADENO ASSOCIATED VIRUS; EXPRESSION VECTOR; GENE TARGETING; GENE THERAPY; HUMAN; MOLONEY LEUKEMIA ONCOVIRUS; ONCOGENE; POXVIRUS; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; TUMOR SUPPRESSOR GENE; VACCINIA VIRUS;

EID: 0031871114     PISSN: 08898588     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0889-8588(05)70013-7     Document Type: Article

References (82)

1. K. Asgari I.A. Sesterhenn D.G. McLeod Inhibition of the growth of pre-established subcutaneous tumor nodules of human prostate cancer cells by single injection of the recombinant adenovirus p53 expression vector Int J Cancer 71 1997 377
2. J. Baar W.J. Storkus M.T. Lotze The immunotherapy of cancer: The role of dendritic cells as potent adjuvants for tumour rejection: Review Article 166 Current Oncology 4 1997 1 7
3. J.R. Bischoff D.H. Kirn A. Williams An adenovirus mutant that replicates selectively in p53-deficient human tumor cells: Research article Science 274 1996 373
4. J.D. Brooks G.S. Bova C.M. Ewing An uncertain role for p53 gene alterations in human prostate cancers Cancer Res 56 1996 3814
5. T.R. Cech B. Bass Biological catalysis by RNA Annu Rev Biochem 55 1986 599
6. A.P. Chen A phase I study of recombinant vaccinia that expresses PSA in adult patients with adenocarcinoma of the prostate RAC Report 9509 1995 126
7. P. Correale K. Walmsley C. Nieroda In vitro generation of human cytotoxic T lymphocytes specific for peptides derived from prostate-specific antigen J Natl Cancer Inst 89 1995 272
8. E.D. Crawford M.A. Eisenberger D.G. McLeod Comparison of bilateral orchiectomy with or without flutamide for the treatment of patients with stage D2 adenocarcinoma of the prostate: Results of NCI intergroup study 0105 J Urol 157 1997 336A
9. K. Culver Z. Ram S. Walbridge In vivo gene transfer with retroviral vector producer cells for treatment of experimental brain tumors Science 256 1992 1550
10. R. Dahiya G. Deng K. Chen p53 tumor-suppressor gene mutations are mainly localised on exon 7 in human primary and metastatic cancer Br J Cancer 74 1996 264
11. T. Dorai H. Kobayashi J.F. Holland Modulation of the platelet derived growth factor-B mRNA expression and cell growth in a human mesothelioma cell line by a hammerhead ribozyme Mol Pharmacol 46 1994 437
12. T. Dorai C.A. Olsson A.E. Katz Development of a hammerhead ribozyme against bcl-2. I. Preliminary evaluation of a potential gene therapeutic agent for hormone-refractory human prostate cancer The Prostate 32 1997 246
13. G. Dranoff E. Jaffee A. Lazenby Vaccination with irradiated tumor cells engineered to secrete murine GM-CSF stimulates potent, specific, and long lasting anti-tumor immunity Proc Natl Acad Sci USA 90 1993 3539
14. F. DuPont L. Tenebaum L.P. Guo Use of an autonomous parvovirus vector for selective transfer of a foreign gene into transformed human cells of different origin and its expression therein J Virol 68 1994 1397
15. J.A. Eastham S.J. Hall I. Sehgal In vivo gene therapy with p53 or p21 adenovirus for prostate cancer Cancer Res 55 1995 5151
16. J.A. Eastham S. Chen I. Sehgal Prostate cancer gene therapy: Herpes simplex virus thymidine kinase gene transduction followed by ganciclovir in mouse and human prostate cancer models Hum Gene Ther 7 1996 515
17. M.A. Eisenberger R. Simon P.J. O'Dwyer A re-evaluation of non-hormonal cytotoxic chemotherapy in the treatment of prostatic carcinoma J Clin Oncol 3 1985 827 841
18. A. Elshami A. Saavedra H. Zhang Gap junctions play a role in the “bystander effect” of herpes simplex virus thymidine kinase/ganciclovir system in vitro Gene Ther 3 1996 85
19. J.E. Engelhardt X. Ye B. Doranz Ablation of E2A in recombinant adenoviruses improves transgene persistence and decreases inflammatory response in mouse liver Proc Natl Acad Sci USA 91 1994 6196
20. T.R. Flotte B.J. Carter Adeno-associated virus vectors for gene therapy Gene Ther 2 1995 357
21. S.J. Hall S.E. Mutchnik M. Shaker Adenovirus mediated HSV-tk gene transduction and ganciclovir treatment for prostate cancer: Suppression of metastasis in an orthotopic model and synergism with androgen ablation J Urol 155 1996 528A
22. G.E. Hanks External-beam radiation therapy for clinically localized prostate cancer: Patterns of care studies in the United States NCI Monogr 7 1988 75 84
23. G.E. Hanks W.R. Lee T.E. Schultheiss Clinical and biochemical evidence of control of prostate cancer at 5 years after external beam radiation J Urol 154 1995 456 459
24. I.R. Hart Tissue specific promoters in targeting systemically delivered gene therapy Semin Oncol 23 1996 154
25. D. He Z.M. Mu Z. Le Adenovirus-mediated expression of PML suppresses growth and tumorigenicity of prostate cancer cells Cancer Res 57 1997 1808
26. H.B. Heidenberg I. Sesterhenn J. Gaddipati Alteration of the tumor suppressor gene p53 in a high fraction of treatment resistant prostate cancer J Urol 154 1995 414
27. Human gene therapy marker/clinical protocols Hum Gene Ther 9 1997 2301
28. N. Kasahara A.M. Dozy Y.W. Kan Tissue-specific targeting of retroviral vectors through ligand-receptor interactions Science 266 1994 1373
29. M. Kawakita J.K. Ritchey M.A. Hudson Effect of canary-pox (ALVAC) virus-mediated cytokine gene expression on prostate tumor growth J Urol 153 suppl 1995 469A
30. JJ Kim, NN Trived, DM Wilson, et al.Molecular and immunological analysis of genetic prostate specific antigen (PSA) vaccine. Oncogene, in press
31. M. Kim M. Wright J. Deshane A novel gene therapy strategy for elimination of prostate carcinoma cells from human bone marrow Hum Gene Ther 8 1997 157
32. D.I. Kleinerman W.W. Zhang S.H. Lin Application of a tumor suppressor (C-CAM1) expressing recombinant adenovirus in androgen-independent human prostate cancer therapy: A pre-clinical study Cancer Res 55 1995 2831
33. H. Kobayashi T. Dorai J.F. Holland Reversal of drug sensitivity in multidrug resistant tumor cells by an MDRI (PGY1) ribozyme Cancer Res 54 1994 1271
34. R.M. Kotin M. Siniscalco R.J. Samulski Site-specific integration by adeno-associated virus Proc Natl Acad Sci USA 87 1990 2211
35. N. Kyprianou H.F. English J.T. Isaacs Programmed cell death during the regression of PC-82 human prostate cancer following androgen ablation Cancer Res 50 1990 3748
36. S.H. Landis T. Murray S. Bolden P.A. Wingo Cancer statistics, 1998 Ca Cancer J Clin 48 1998 6 29
37. E.C. Lattime S.S. Lee L.C. Eisenlohr M.J. Mastrangelo In situ cytokine gene transfection using vaccinia virus vectors Semin Oncol 23 1996 88
38. C. Lee L. Meide K. Sie Prostate-specific antigen promoter driven gene therapy targeting DNA polymerase-alpha and topoisomerase II alpha in prostate cancer Anticancer Res 16 1996 1805
39. S.S. Lee L.C. Eisenlohr P.A. McCue Intravesicle gene therapy: In vivo gene transfer using recombinant vaccinia virus vectors Cancer Res 54 1994 3325
40. S.B. Malkowicz Serum prostate-specific antigen elevation in the post-radical prostatectomy patient Urol Clin North Am 23 1996 665
41. T.J. McDonnell P. Troncoso S.M. Brisbay Expression of the proto-oncogene bcl-2 in the prostate and its association with the emergence of androgen independent prostate cancer Cancer Res 50 1992 6565
42. C. McKeon R.J. Samulski NIDDK workshop on AAV vectors: Gene transfer into quiescent cells Hum Gene Ther 7 1996 1615
43. A.D. Miller Retroviral vectors Curr Top Microbiol Immunol 1158 1992 1
44. B. Moss Vaccinia virus: A tool for research and vaccine development Science 252 1991 1662
45. C.A. Mullen M.M. Coale R. Lowe Tumors expressing the cytosine deaminase gene can be eliminated in vivo with 5-fluorocytosine and induce protective immunity to wild type tumor Cancer Res 54 1994 1503
46. G. Murphy B. Tjoa H. Ragde Phase I clinical trial: T-cell therapy for prostate cancer using autologous dendritic cells pulsed with HLA-A0201-specific peptides from prostate-specific membrane antigen The Prostate 29 1996 371
47. G.J. Nabel E.G. Nabel Z.Y. Yang Direct gene transfer with DNA-liposome complexes in melanoma: Expression, biologic activity, and lack of toxicity in humans Proc Natl Acad Sci USA 90 1993 1307
48. M. Ohori J.R. Goad T.M. Wheeler Can radical prostatectomy alter the progression of poorly differentiated prostate cancer? J Oncol 152 1994 1843 1846
49. S. Pang J. Dannull R. Kaboo Identification of a positive regulatory element responsible for tissue-specific expression of prostate-specific antigen Cancer Res 57 1997 495
50. S. Pang S. Taneja K. Dardashti Prostate tissue specificity of the prostate-specific antigen promoter isolated from a patient with prostate cancer Hum Gene Ther 6 1995 1417
51. A.W. Partin C.R. Pound J.Q. Clemens Serum PSA after anatomic radical prostatectomy Urol Clin North Am 20 1993 713
52. A.W. Partin J.E. Oesterling The clinical usefulness of prostate specific antigen: Update 1994 J Urol 152 1994 1358
53. D. Paulson H.K. Lyerly A phase I study of autologous human IL-2 modified tumor cells in patients with locally advanced or metastatic prostate cancer RAC Report 9510 1995 132
54. T.L. Ratliff Molecular research in cancer: Future clinical applications Acta Urologica Belgica 64 2 1996 53
55. P.H.J. Riegman R.J. Vlietsra Vander Korput J.A. The promoter of the prostate specific antigen gene contains a functional androgen responsive element Mol Endocrinol 5 1991 1921
56. R. Rodriguez E.R. Schuur H.Y. Lim Prostate attenuated replication competent adenovirus (ARCA) CN706: A selective cytotoxic for prostate-specific antigen-positive Cancer Res 57 1997 2559
57. B. Salmons W.H. Gunzburg Targeting of retroviral vectors for gene therapy Hum Gene Ther 4 1993 129
58. R.J. Samulski X. Zhu X. Xiao Targeted integration of adeno-associated virus (AAV) into human chromosome 19 EMBO J 10 1991 3941
59. M.G. Sanda S.R. Ayyagari E.M. Jaffee Demonstration of a rational strategy for human prostate cancer gene therapy J Urol 151 1994 622
60. P.T. Scardino T.C. Thompson S.L.C. Woo Phase I study of adenoviral vector delivery of the HSV-tk gene and the intravenous administration of ganciclovir in men with local recurrence of prostate cancer after radiation therapy RAC Report 9601 1996 144
61. E.R. Schuur G.A. Henderson L.A. Kmetec Prostate-specific antigen expression is regulated by an upstream enhancer J Biol Chem 271 1996 7043
62. Sellers W.R. Kaelin W.G. Jr Role of the retinoblastoma protein in the pathogenesis of human cancer J Clin Oncol 15 1997 3301
63. J.W. Simons E.M. Jaffee C.E. Weber Bioactivity of autologous irradiated renal cell carcinoma vaccines generated by ex vivo granulocyte-macrophage colony-stimulating factor gene transfer Cancer Res 57 1997 1537
64. J.G. Sinkovics J. Horvath Can virus therapy of human cancer be improved by apoptosis induction? Med Hypotheses 44 1994 359
65. M.S. Steiner C.T. Anthony Y. Lu Gene therapy for the treatment of advanced prostate cancer by in vivo transduction with prostate-targeted retroviral vectors expressing anti-sense C-MYC RNA J Urol 155 1996 117
66. M.S. Steiner J.T. Holt Gene therapy for the treatment of advanced prostate cancer by in vivo transduction with prostate-targeted retroviral vectors expressing anti-sense c-myc RNA RAC Report 9509 1995 123
67. T.G. Stohmeyer D.J. Samon Protooncogenes and tumor suppressor genes in human urological malignancies J Urol 151 1994 1479
68. W.H. Sun J.K. Burkholder J. Sun In vivo cytokine gene transfer by gene gun reduces tumor growth in mice Proc Natl Acad Sci USA 92 1995 2889
69. S.S. Taneja A. Belldegrun K. Dardashti In vitro target specific gene therapy for prostate for an androgen-independent and metastatic human prostate cancer model Proc Am Assoc Cancer Res 37 1996 349
70. I.F. Tannock D. Osoba M.R. Stockler Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: A Canadian randomized trial with palliative end points J Clin Oncol 14 1996 1756 1764
71. J.D. Thompson D. Macejak L. Couture Ribozymes in gene therapy Nat Med 1 1995 277
72. B.A. Tjoa S.J. Erickson V.A. Bowes Follow-up evaluation of prostate cancer patient infused with autologous dendritic cells pulsed with PSMA peptides The Prostate 32 1997 272
73. Q.T. Trinh E.A. Austin D.M. Murray Enzyme/prodrug gene therapy: Comparison of cytosine deaminase/5-fluorocytosine versus thymidine kinase/ganciclovir enzyme/prodrug systems in a human colorectal carcinoma cell line Cancer Res 55 1995 4808
74. R. Umbas J.A. Schalken T.W. Aalders Expression of the cellular adhesion molecule e-cadherin is reduced or absent in high-grade prostate cancer Cancer Res 52 1992 5104
75. J. Vieweg D. Boczkowski K.M. Roberson Efficient gene transfer with adeno-associated virus-based plasmids complexed to cationic liposomes for gene therapy of human prostate cancer Cancer Res 55 1995 2366
76. J. Vieweg F.M. Rosenthal R. Bannerji Immunotherapy of prostate cancer in the Dunning rat model: Use of cytokine gene modified tumor vaccines Cancer Res 54 1994 1760
77. N.J. Vogelzang One hundred thirteen men with hormone-refractory prostate cancer died today J Clin Oncol 14 1996 1753
78. C. Yang C. Cirielli M.C. Capogrossi Adenovirus-medicated wild-type p53 expression induces apoptosis and suppresses tumorigenesis of prostatic tumor cells Cancer Res 55 1995 4210
79. N.S. Yang W.H. Sun Gene gun and other non-viral approaches for cancer gene therapy Nat Med 1 1995 481
80. Y. Yang Q. Li H.C.J. Ertl Cellular and humoral immune responses to viral antigens create barriers to lung-directed gene therapy with recombinant adenoviruses J Virol 60 1995 2004
81. K.S. Zier B. Gansbacher Tumour cell vaccines that secrete interleukin-2 (IL-2) and interferon gamma (INF gamma) are recognized by T cells while resisting destruction by natural killer (NK) cells Eur J Cancer 32A 1996 1408
82. H. Zincke J.E. Oesterling M.L. Blute Long-term (15 years) results after radical prostatectomy for clinically localized (stage T2c or lower) prostate cancer J Urol 152 1994 1850